tbuckley/cabot-search huggingface dataset:
PTU-092 Plasma Angiopoietin 2, A Circulating Marker of Endothelial Cell Activation, Is Elevated in Acute Alcoholic Hepatitis
Authors: VT Kronsten, J Ryan, GM Vijay, Y Ma, D Shawcross
Journal: Gut (2016)

<h3>Introduction</h3> Acute Alcoholic Hepatitis (AAH) is the most florid form of alcohol-related liver disease (ALD) with a mortality rate in the first 28 days of over 30%. These patients are particularly prone to developing infections with a high risk of developing multiple organ failure including hepatic encephalopathy, renal failure and circulatory collapse. The vascular endothelium becomes activated in severe sepsis allowing the influx of inflammatory cells from the circulation. Angiopoeitin (ANG) 1 and 2 are key to endothelial cell (EC) activation. On activation by stimuli such as pro-inflammatory cytokines, ECs release Wiebel-Palade bodies liberating ANG 2. ANG 2 competitively inhibits ANG 1, renders the endothelium responsive to further cytokine stimulation and disrupts cell-cell adhesion increasing vascular permeability. In sepsis plasma levels of ANG 1 and 2 have been implicated as potential prognostic biomarkers. Considering that patients with severe AAH and ALD have evidence of a systemic pro-inflammatory milieu this study measured plasma levels of ANG 1 and ANG 2 as surrogate biomarkers of EC dysfunction. <h3>Methods</h3> Thirty patients with severe AAH (Maddrey’s discriminant factor &gt;32) and a history of alcohol excess (≥80 g/day for males; ≥60 g/day for females) were studied at presentation prior to any therapy being prescribed and compared to healthy controls (HC) (n = 7). Twenty one patients with ALD (Child Pugh C) were also studied. Exclusion criteria included alcohol abstinence &gt;6 weeks, other causes of liver disease, malignancy, concomitant use of immunosuppression ≤6 months and AST &gt; 500 IU/L. Plasma levels of ANG 1 and ANG 2 were measured by enzyme-linked immunosorbent assay (ELISA). <h3>Results</h3> Plasma levels of ANG 2 were found to be significantly higher in the AAH group compared to HC (p &lt; 0.0001) and in the AAH group compared to ALD (p &lt; 0.05). The ANG 2:1 ratio was also significantly higher in the AAH group compared to HC (p &lt; 0.001), and in the AAH group compared to ALD (p &lt; 0.05). ANG 2 and ANG 2:1 ratio trended towards being higher in culture positive AAH patients (p = 0.065). In this study there was no statistically significant difference in any marker level between non-surviving (at 1 month) and surviving AAH patients. <h3>Conclusion</h3> Plasma levels of ANG 2, a soluble biomarker of endothelial activation, and the ANG 2:1 ratio are increased in AAH and could predict the subsequent development of organ failure. <h3>Disclosure of Interest</h3> None Declared
Suicide Gene (HSVtk) Ablation of Hematopoietic Stem Cells and Their Progeny In the Rhesus Macaque Model: An Approach to Deletion of Dangerous Clones.
Authors: Cecilia Barese, Connor King, Stephanie Sellers, Allen E Krouse, Mark E Metzger, Catia Traversari, Claudio Bordignon, Steven M. Kornblau, Frank Marini, Robert E Donahue, Cynthia E. Dunbar
Journal: Blood (2010)
Oxidative Stress Contributes to Overactive Bladder in the Transgenic Sickle Cell Mouse
Authors: Fabio Henrique Silva, Celso Saragosa Ramos Filho, Fabiano Beraldi Calmasini, Eduardo Costa Alexandre, Roger Barbosa Ferreira, Mariana Goncalves de Oliveira, Mário Angelo Claudino, Carla Fernanda Franco-Penteado, Edson Antunes, Fernando F Costa
Journal: Blood (2015)
SP0138 The Fruit Fly, as A Tool To Study ER Stress
Authors: S. Gaumer
Journal: Annals of the Rheumatic Diseases (2016)

Endoplasmic Reticulum (ER) stress is a cellular event found misregulated in numerous diseases including osteoporosis, osteoarthritis and inflammatory pathologies. ER stress is also involved in physiological events such as fibroblast differentiation after injuries. Numerous proteins transit through the ER in which they are folded and glycosylated. This organelle is also responsible for the synthesis of lipids and calcium homeostasis. If any of these missions fails, aggregating proteins accumulate and become cytotoxic, leading to devastating pathologies. An adaptive response, known as the Unfolded Protein Response (UPR), normally prevents such accumulation by resolving the stress or ultimately eliminating the cell. <i>Drosophila</i> is a powerful model organism to study ER stress. Indeed, the UPR is largely conserved between insects and humans. We show how <i>Drosophila</i> genetics and its numerous tools can be easily used to show that both protein aggregation and calcium dyshomeostasis activate the same PERK/ATF4 branch of the UPR to induce both caspase-dependent apoptosis and a JNK-dependent hormonal response that allows tissue homeostasis. Interestingly, this response is tissue-specific. <h3>Disclosure of Interest</h3> None declared
Inhibition of T Lymphocyte (TL) Proliferation by Mesenchymal Stem Cells (MSCs): Role of Cell Contact between MSCs and TL, Role of MSCs Dose Effect, and Role of Soluble Factors and Adhesion Molecules Expressed by MSCs.
Authors: Aisha Nasef, Alain Chapel, Morad Benshidom, Yizhuo Zang, Christelle Mazurier, Sandrine Bouchet, Manuel Lopez, Norbert Claude Gorin, Dominique Thierry, Loic Fouillard
Journal: Blood (2004)
Janus Kinase (JAK)-2 Does Not Play a Role in Bcr-Abl Signaling in Philadelphia Chromosome (Ph)-Positive (p190) Acute Lymphoblastic Leukemia (ALL) Cells.
Authors: Stefan H. Faderl, Quin Van, Patricia E. Koch, David M. Harris, Inbal Hallevi, Zhiming Liu, Yongtao Wang, Alessandra Ferrajoli, Zeev Estrov
Journal: Blood (2007)
SAT0038 Confirmation of Serological Antibodies against Novel Citrullinated Proteins in Early Rheumatoid Arthritis
Authors: P. Schulz-Knappe, P. Budde, A. Lueking, P. Schriek, H. Goehler, H.-D. Zucht, J. Detert, G.-R. Burmester, M. Schneider, J. Richter, S. Vordenbäumen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid Factors (RF) and autoantibodies against citrullinated proteins (ACPA) are part of the diagnosis of rheumatoid arthritis (RA). Unfortunately these analytes lack sensitivity especially in early phases of RA. By way of screening proteins from a human protein library of over 7,000 proteins we discovered over 20 novel citrullinated antigens targeted by ACPAs in CCP positive as well as in 5–10% of CCP negative RA patients suggesting added diagnostic potential. <h3>Objectives</h3> To challenge novel human proteins as biomarkers for early RA which exhibited reactivities in citrullinated format against early and late RA patient serum samples we set to analyze sufficiently large, new cohorts of patients with early and established RA against the candidate proteins both in their citrullinated and non-citrullinated form. We also planned to veify single antigen performance by comparison to established benchmark proteins and marketed assays. <h3>Methods</h3> 34 novel citrullinated antigens were analyzed in serum samples from independent cohorts of 300 CCP positive and 151 CCP negative patients with early RA, 100 healthy volunteers and 50 patients with established RA. All samples were analyzed in a multiplexed, bead-based array on Luminex FlexMAP3D, compared to reactivities against known citrullinated proteins (vimentin, fibrinogen, enolase) and subsequently in 3 commercially available anti-CCP-assays. <h3>Results</h3> We confirmed novel citrullinated antigens targeted by ACPAs as markers of RA. The citrullinated antigens are highly reactive compared to their non-citrullinated forms in mature RA and in CCP positive samples of patients with early RA. 4 single antigens reach high overlap to established CCP-Assays each with &gt;75% sensitivity at 97% specificity. Increased reactivity of novel antigens was identified in up to 10% of CCP negative samples suggesting the presence of additional citrullinated epitopes not present in commercial CCP assays used in this study. <h3>Conclusions</h3> Novel citrullinated antigens discovered by large scale “omics” screening via Luminex bead based arrays were confirmed in novel samples of early and established RA, especially in CCP positive samples. Reactivity in 10% CCP negative samples suggests added diagnostic value. <h3>Disclosure of Interest</h3> P. Schulz-Knappe Employee of: Protagen AG, P. Budde Employee of: Protagen AG, A. Lueking Employee of: Protagen AG, P. Schriek Employee of: Protagen AG, H. Goehler Employee of: Protagen AG, H.-D. Zucht Employee of: Protagen AG, J. Detert: None declared, G.-R. Burmester: None declared, M. Schneider: None declared, J. Richter: None declared, S. Vordenbäumen: None declared
A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms
Authors: Animesh Pardanani, Geeta George, Terra Lasho, William J. Hogan, Mark R. Litzow, Kebede Begna, Curtis A. Hanson, Rose Fida, Chris Burns, Gregg D Smith, Ayalew Tefferi
Journal: Blood (2010)
Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients
Authors: Daniel Landi, Michele Beckman, Nirmish Shah, Paula Bockenstedt, John A. Heit, Roshni Kulkarni, Marilyn Manco-Johnson, Stephan Moll, Claire S. Philipp, Judith C. Andersen, Thomas L. Ortel
Journal: Blood (2010)
Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia.
Authors: William Arcese, Raffaella Cerretti, Stella Santarone, Gottardo De Angelis, Pasqua Bavaro, Manuela Testi, Laura Cudillo, Alessandra Picardi, Elsa Pennese, Gabriele Papalinetti, Teresa Dentamaro, Eleonora Ceresoli, Benedetta Mariotti, Fabio Di Piazza, Paolo Di Bartolomeo
Journal: Blood (2012)
FRI0375 Clinical Improvement According To Patient Reported Outcomes in Patients with Polymyalgia Rheumatica: A Longitudinal Analysis from Routine Care: Table 1
Authors: I. Castrejon, S.L. Everakes, A. Nika, W. Sequeira, T. Pincus
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several outcomes and clinical response measures have been used in patients with polymyalgia rheumatica (PMR), but there is no consensus about the optimal endpoint for evaluating response to treatment. A PMR activity score has been proposed which includes three patient reported outcomes (PROs)<sup>1</sup>. RAPID3 is an index found on a multidimensional health assessment questionnaire (MDHAQ) only including PROs, which is effective to document improvement not only in RA but also in other rheumatic diseases<sup>2</sup> <h3>Objectives</h3> To prospectively evaluate the performance of RAPID3 and other PROs included on the MDHAQ to document improvement in clinical status over time in patients with PMR. <h3>Methods</h3> This study was conducted at an academic rheumatology center at which all patients complete a MDHAQ, which includes 0–10 scores for physical function (FN), pain (PN), and patient global estimate (PATGL), compiled into a 0–30 RAPID3. The MDHAQ also scores fatigue, morning stiffness, self-reported joint counts and demographic data. Data collection included MDHAQ, acute-phase reactants, and prednisone dose. PMR patients with complete data seen between 2010 and 2014 were included. A baseline visit and the most recent visit were compared using paired t-test and McNemar9s test. Spearman correlation analysis for non-normally distributed variables was performed between RAPID3 and ESR and CRP. <h3>Results</h3> 34 PMR patients seen in routine care were included: 59% were females, 71% Caucasian, and mean age was 71.6 years. The mean duration from a baseline visit to most recent visit was 15.5 months. At initial presentation, RAPID3 was 12.2, FN 2.2, pain 5.3, and PATGL 4.7, fatigue 3.9, and morning stiffness 63.1 minutes; 64.7% of the patients had painful hips, 79.4% had painful shoulders, 73.5% had abnormal ESR, and 70.6% had abnormal CRP. Significant improvement was seen between baseline and last visit in mean level of RAPID3 and all other MDHAQ measures, except fatigue (p&lt;0.05), as well as ESR and CRP (Table). The mean dose of prednisone was decreased from 12.2 mg at first visit to 4.3 mg at most recent visit. The RAPID3 was significantly correlated with ESR (rho=0.52), and with CRP (rho=0.50). <h3>Conclusions</h3> In patients with PMR, improvement was seen according to PROs included on a self-reported MDHAQ questionnaire in a similar range to ESR and CRP, documenting effective response to prednisone. <h3>References</h3> Leeb BF, Bird HA. Ann Rheum Dis 2004;63(10):1279–83. Castrejon I, Bergman MJ, Pincus T. J Clin Rheumatol 2013;19:169–74. <h3>Disclosure of Interest</h3> None declared
Multicenter Retrospective Study on the Development of Peripheral Lymphocytosis During Second-Line Dasatinib Therapy for Chronic Myeloid Leukemia
Authors: Ha Yeon Lee, Su Jin Lee, Boram Ha, Jun Ho Yi, Chul Won Jung, Dae-Young Kim, Je-Hwan Lee, Kyoo Hyung Lee, Sang Kyun Sohn, Sung Hyun Kim, Won-Sik Lee, Joon Seong Park, Ho-Young Yhim, Jae-Yong Kwak, Hyeoung Joon Kim, Yeo-Kyeoung Kim, Inho Kim, Seonyang Park, Dong Hwan (Dennis) Kim
Journal: Blood (2010)
THU0588 IGG4-Related Disease: Features and Treatment Response in An Asian Cohort
Authors: W. Fong, I. Liew, D. Tan, K.H. Lim, A. Low, Y.Y. Leung
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Most descriptions of IgG4-related disease (IgG4-RD) have been from Japanese and Caucasian populations. <h3>Objectives</h3> To describe the clinical, laboratory, histological features and treatment outcomes of IgG4-RD in multi-ethnic Asian patients in Singapore. <h3>Methods</h3> Patients diagnosed with IgG4-RD were identified from a Rheumatology and Gastroenterology patient database in a tertiary hospital. Demographics, clinical manifestations, laboratory results, disease activity, clinical outcomes and therapeutics used were derived from medical records. Disease activity was assessed by the IgG4-RD Responder Index. <h3>Results</h3> 42 patients (76% male) were included; all had a diagnosis of IgG4-RD made by a rheumatologist or gastroenterologist experienced in IgG4-RD. 79% and 17% fulfilled the 2011 comprehensive diagnostic criteria for IgG4-RD<sup>1</sup> for definite and probable IgG4-RD respectively. 81% were Chinese and 19% were Malays. Mean age of the cohort was 62.7 ± 13.1 years. Mean age of diagnosis was 57.5 ± 12.8 years. Mean duration of disease was 4.5 ± 3.5 years. Common initial manifestations included jaundice (52%), abdominal pain (36%), swollen salivary glands (26%) and constitutional symptoms (21%). Only 36% had a history of allergy. 83% had ≥1 organ involvement, including autoimmune pancreatitis (67%), lymphadenopathy (45%), sclerosing cholangitis (43%), sialadenitis (31%) and dacryoadenitis (21%). 86% (6/7) of patients with isolated lesions involved only the pancreas. There was no gender difference in type of organ involvement. Erythrocyte sedimentation rate (ESR), IgG1, IgG2, IgG3, IgG4 levels were elevated in 83%, 22%, 74%, 37%, 41% of patients respectively. IgG4 levels did not correlate with ESR, age, disease duration, IgE levels and number of organs involved. The most common histopathological feature was that of &gt;10 IgG4+ cells per high power field (66%), followed by lymphocytic infiltration (51%) and storiform fibrosis (51%). Only 7% had obliterative phlebitis. 94% (34/36) of patients were treated with moderate to high doses of glucocorticoids, including 17 patients with combination immunosuppressants. Of these, all patients responded to therapy by 3 months. With a mean follow-up of 4.8 ± 3.1 years, 69% (25/36) needed low dose of glucocorticoids to maintain disease remission. 26% had relapse of disease, of which 82% had disease recurrence in the same organs. <h3>Conclusions</h3> Pancreatitis, lymphadenopathy and cholangitis were the commonest manifestations in Asians with IgG4-RD. All patients responded to glucocorticoid therapy by 3 months, two-thirds required maintenance therapy with glucocorticoids, and one-quarter developed relapse of disease. <h3>References</h3> Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30. <h3>Disclosure of Interest</h3> None declared
RGD-porphyrin conjugates: Solid phase synthesis and in vitro phototoxicity using A549 and EMT-6 cells
Authors: Benoît Di Stasio, Muriel A. Barberi-Heyob, Céline Frochot, François Guillemin, Marie-Laure Viriot
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

4584 

Integrin receptors are heavily expressed on many tumour cells such as osteosarcomas, neuroblastomas and lung carcinomas. Integrins are cell surface receptors that mediate both physical and functional interactions of the cell and its surrounding extracellular matrix. Integrins are implicated in the transduction of biochemical signals regulating cell survival, cell migration, cell proliferation, differentiation and cell death. Integrin receptors are heterodimeric single transmembrane receptors consisting of an α and a β subunits. It has been shown that αvβ3 integrin is implicated in angiogenesis as well as tumor growth and metastatic processes. The tripeptide RGD (Arg-Gly-Asp) is a cell attachment site for a number of extracellular matrix proteins. Photodynamic therapy (PDT) is a promising new binary treatment for several malignant and non-malignant conditions. PDT combines a light activated drug (photosensitizer) with the light of an appropriate wavelength to generate reactive oxygen species. The labeling of photosensitizers with RGD peptide could increase its delivery to the target tissue. We report a convenient solid-phase synthesis, photochemical characterization and biological activities of second-generation photosensitizers bearing the RGD tripeptide, designed for photodynamic cancer therapy. Adenocarcinoma lung cancer cells (A549, expressing RGD binding receptors) and murine mammary cancer cells (EMT-6, lacking RGD binding receptors) were treated with photosensitizers (porphyrin and chlorin) conjugated with RGD sequence. A three-hour exposure with conjugated porphyrin or chlorin improved the cytotoxic effect of photodynamic therapy in A549 cell line, as assessed by MTT assay.
Gene Expression Profiling Predicts Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.
Authors: Norman J. Lacayo, Maureen O’Brien, Shweta Jain, Soheil Meshinchi, Ron Yu, Dejan Juric, Myron N. Chang, Robert Tibshirani, Yaddanapudi Ravindranath, Howard J. Weinstein, Branimir I. Sikic, Gary Van Houten Dahl
Journal: Blood (2006)
Outcome and Long Term Toxicity of the LNH- PRO Trial after 12 Year Median Follow-up, in Patients with Indolent Non Hodgkin's Lymphoma Who Received Immunochemotherapy with CVP and Interferon-alfa2b (IFNα2b)
Authors: Jimena Cannata-Ortiz, Concepción Nicolás, Ana García-Noblejas, Javier Lopez, Pilar Sabin, Pilar Zamora, Maria José Requena, Reyes Arranz
Journal: Blood (2014)
Sensitivity of Childhood Acute Lymphoblastic Leukemia (ALL) to Idarubicin Is Significantly Higher Than to Daunorubicin Treatment Based on Ex Vivo Apoptosis Induction.
Authors: Aram Prokop, Banu Bagci, Guenaelle Lingfeld, Lucia Badiali, Karin Garbrecht, Ulrike Mietzsch, Thomas Wieder, Peter T. Daniel, Günter Henze
Journal: Blood (2004)
Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse
Authors: Guillermo Montalban-Bravo, Hagop M. Kantarjian, Punit L Jain, Guillermo Garcia-Manero, Farhad Ravandi, Jorge E. Cortes, Naval Daver, Koichi Takahashi, Nitin Jain, Srdan Verstovsek, Tapan Kadia, Sherry Pierce, Elias Jabbour
Journal: Blood (2015)
Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.
Authors: Emilio Iannitto, Viviana Minardi, Paolo G. Gobbi, Giuseppina Calvaruso, Caterina Stelitano, Luca Baldini, Francesco Merli, Mario Petrini, Luigi Marcheselli, Caterina Mammi, Stefano De Cantis, Vincenzo Abbadessa, Massimo Federico
Journal: Blood (2006)
SAT0493 Tuberculosis of The Hand: Clinical Presentation and Treatment
Authors: M.A. Sbai, H. Sahli, W. Khoffi, A. Ben Tekaya, R. Tekaya
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The tuberculosis remains one of the most world wide spread infectious diseases. The ostéoarticular localization is rare, affecting the hand remains exceptional. The incidious presentation, the poor symptomatic character of the tubercular dactylitis may explain the constant delay in the diagnosis. It is often delayed and confused essentially with bone tumors which imply histological confirmation. <h3>Objectives</h3> To study the epidemio-clinical features, stages, therapeutics and course of tuberculosis of the hand. <h3>Methods</h3> We made a retrospective study of 14 medical records of cases of tuberculosis involving the hands in an orthopedic department over the last ten years. We collected and analyzed the clinical, bacteriological, radiological and therapeutic data. <h3>Results</h3> The mean age was 45 years. There were 9 men and 5 women. A manual work was noted in 10 cases. Two patients had a diabetes mellitus and one breast cancer. The dominant side was achieved in 60% of cases. Mean symptoms duration was 3.6 months. Lesions are divided into 6 cases of pseudotumoral tuberculosis of soft tissue of the hand, arthritis and osteoarthritis in 5 cases and tenosynovitis in 3 cases. The ring and little fingers are the most affected fingers. Biopsy was done in all cases. Anti-tubercular chemotherapy was indicated for all patients: isoniazid, rifampicin, pyrazinamide and ethambutol for 2 months followed by isoniazid and rifampicin during 10 months. These antibiotics were combined with immobilization in all cases. Good outcome was seen in the 14 cases. <h3>Conclusions</h3> Tuberculosis should be suspected in cases of longstanding pain and swelling of a finger especially in an endemic area. Efficiency of anti-tubercular treatment remains undisputed. The surgical indications are limited to the biopsy, usually essential to the diagnosis. <h3>Disclosure of Interest</h3> None declared
SP0016 Exercise Therapy To Reduce Pain in Knee Osteoarthritis: Mechanisms and Treatment Optimization
Authors: M. Van Der Leeden
Journal: Annals of the Rheumatic Diseases (2016)

Exercise is effective in reducing pain in knee osteoarthritis (moderate effect size)<sup>1</sup>. The working mechanisms of the positive effects of exercise therapy in knee OA are not fully elucidated. Improvement in physiological factors such as upper leg muscle strength, joint range of motion and proprioception have been found to be related to improvement in pain and activity limitations<sup>2</sup>, but also psychosocial and general health related mechanism might be involved. Additionally, reduction in local as well as systemic inflammation seems to be a working mechanism of exercise therapy, although evidence is still limited. Severe knee pain hampers the ability to participate in exercise therapy. Patients with knee OA who experience severe knee pain form a substantial group of patients with knee OA. These patients may benefit insufficiently from exercise therapy. Recently, an intervention protocol which combines standardized analgesic prescription and exercise therapy has been developed<sup>3</sup>. The purpose of this intervention protocol was to reduce pain by optimization of analgesics, thereby allowing the patient to participate in exercise therapy. The feasibility and outcome of this combined intervention will be presented. <h3>References</h3> Fransen et al, Br J Sports Med 2015 Runhaar et al, Osteoarthritis Cartilage 2015 van Tunen et al, Arthritis Care Res 2016. <h3>Disclosure of Interest</h3> None declared
BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.
Authors: Cihangir Duy, Leandro Cerchietti, J. Jessica Yu, Weimin Ci, Srividya Swaminathan, Rahul R. Nahar, Soo-mi Kweon, Lars Klemm, B. Hilda Ye, Ari Melnick, Markus Müschen
Journal: Blood (2009)